Strides Pharma Science Ltd.
1,126.80+0.4 (+0.04%)
3 Jul, 3:30 PM
Analyst Ratings and Targets
Strides Pharma Science Ltd. analyst ratings, buy/sell/hold recommendations and 12-month price targets from leading brokerages.
Analyst Ratings
Total recommendations
1
Analysts with Strong Buy
0
Analysts with buy
1
100.0%
100% of analysts have buy or strong buy on this stock implying positive street outlook.
Analysts with Strong Buy
0
Analysts with buy
1
Analysts with hold
0
Analysts with Sell
0
Analysts with Strong Sell
0
Target Price
Current market price
₹ 1,126.80
Median target price
₹ 1,410.00 (25.13%)
Highest target price
₹ 1,410.00 (25.13%)
Average target price
₹ 1,410.00 (25.13%)
Lowest target price
₹ 1,410.00 (25.13%)
Financial Estimates
Strides Pharma Science Ltd. analyst consensus estimates for revenue, EBITDA, PAT and EPS (consolidated) for the next 2 financial years on a rolling basis.
EPS for FY Mar 26: ₹ 64.97 /share
Estimated EPS for FY Mar 27
Median
₹ 68.00(4.66 %)
High
₹ 68.00(4.66 %)
Mean
₹ 68.00(4.66 %)
Low
₹ 68.00(4.66 %)
Estimated EPS for FY Mar 28
Median
₹ 100.70(24.50 %)
High
₹ 100.70(24.50 %)
Mean
₹ 100.70(24.50 %)
Low
₹ 100.70(24.50 %)
BPS for FY Mar 26: -
Estimated BPS for FY Mar 27
Median
-
High
-
Mean
-
Low
-
Estimated BPS for FY Mar 28
Median
-
High
-
Mean
-
Low
-
Sales for FY Mar 26: ₹ 4.86 k Cr
Estimated Sales for FY Mar 27
Median
₹ 5.81 k Cr(19.54 %)
High
₹ 5.81 k Cr(19.54 %)
Mean
₹ 5.81 k Cr(19.54 %)
Low
₹ 5.81 k Cr(19.54 %)
Estimated Sales for FY Mar 28
Median
₹ 7.09 k Cr(20.80 %)
High
₹ 7.09 k Cr(20.80 %)
Mean
₹ 7.09 k Cr(20.80 %)
Low
₹ 7.09 k Cr(20.80 %)
Estimates Revision
How Strides Pharma Science Ltd. analyst consensus for revenue and earnings has been revised over the last 12 months.
EPS revisions in the last 12 months
EPS estimate for FY end:
Mar 2027
Frequently Asked Questions
What is the analyst consensus recommendation for Strides Pharma Science Ltd.?
The analyst consensus for Strides Pharma Science Ltd. is Buy. Out of 1 analysts covering the stock, 1 have a Buy or Strong Buy rating (100%), 0 have a Hold and 0 have a Sell or Strong Sell rating.
What is the target price for Strides Pharma Science Ltd.?
The median analyst target price for Strides Pharma Science Ltd. is ₹ 1,410.00, with a high target of ₹ 1,410.00 and a low target of ₹ 1,410.00. The mean (average) target is ₹ 1,410.00.
How many analysts cover Strides Pharma Science Ltd.?
1 analysts actively cover Strides Pharma Science Ltd.: 0 Strong Buy, 1 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
What is the upside or downside potential for Strides Pharma Science Ltd. from the current price?
Based on the current market price of ₹ 1,126.80 and the median analyst target of ₹ 1,410.00, there is a 25.1% upside potential for Strides Pharma Science Ltd. according to analyst consensus.
What is the revenue estimate for Strides Pharma Science Ltd. for the next financial year?
Analyst consensus estimates Strides Pharma Science Ltd.'s revenue for FY 2027 at ₹ 5.81 k Cr (+19.5% growth), with analyst estimates ranging from ₹ 5.81 k Cr (low) to ₹ 5.81 k Cr (high). Full revenue and earnings estimates are in the Financial Estimates section.
What is the EPS estimate for Strides Pharma Science Ltd.?
The current trailing twelve month EPS of Strides Pharma Science Ltd. is 60.34. Analyst consensus estimates EPS for FY 2027 at ₹ 68.00 per share (+4.7% growth). Forward EPS estimates are in the Financial Estimates section.
What is the BPS estimate for Strides Pharma Science Ltd.?
Book Value Per Share (BPS) estimates for Strides Pharma Science Ltd. from analyst consensus are available in the Financial Estimates section of the Forecast tab. BPS reflects the net asset value per share and is used to gauge price-to-book valuation.
Are analysts bullish or bearish on Strides Pharma Science Ltd.?
Analyst sentiment on Strides Pharma Science Ltd. leans buy: 100% of analysts have a Buy or Strong Buy rating. The consensus outlook is updated as brokerages revise their ratings — see the Estimates Revision section for how views have shifted.
Has the analyst consensus for Strides Pharma Science Ltd. been revised recently?
Estimate revision history for Strides Pharma Science Ltd. is available in the Estimates Revision section of the Forecast tab, showing how analyst consensus for revenue and earnings has changed over the past 12 months.
What is the current PE ratio of Strides Pharma Science Ltd. compared to the target implied PE?
The current trailing PE of Strides Pharma Science Ltd. is 18.67. Based on the median analyst target price of ₹ 1,410.00 and TTM EPS of 60.34, the target-implied forward PE is approximately 23.4x.